Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Viviana Lacava, Vincenzo Pellicanò, Carmen Ferrajolo, Valeria Cernaro, Luca Visconti, Giovanni Conti, Michele Buemi & Domenico Santoro. (2017) Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opinion on Investigational Drugs 26:4, pages 445-462.
Read now
Read now
Kristy Iglay, Shannon E. Cartier, Virginia M. Rosen, Victoria Zarotsky, Swapnil N. Rajpathak, Larry Radican & Kaan Tunceli. (2015) Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Current Medical Research and Opinion 31:7, pages 1283-1296.
Read now
Read now
Atul Ashok Kalanuria, Paul Nyquist & Geoffrey Ling. (2012) The prevention and regression of atherosclerotic plaques: emerging treatments. Vascular Health and Risk Management 8, pages 549-561.
Read now
Read now
Tarek AN Ahmed, Ioannis Karalis & J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, pages 203-233.
Read now
Read now
Jerry R Colca. (2007) Discontinued drugs in 2006: renal, endocrine and metabolic drugs. Expert Opinion on Investigational Drugs 16:10, pages 1517-1523.
Read now
Read now
Articles from other publishers (52)
Dominic D. Martinelli. (2023) Machine learning for metabolomics research in drug discovery. Intelligence-Based Medicine 8, pages 100101.
Crossref
Crossref
Shuyan Gu, Xiaoqian Hu, Lizheng Shi, Xuemei Zhen, Xueshan Sun, Minzhuo Huang, Yuxuan Gu & Hengjin Dong. (2022) Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:23, pages 7094.
Crossref
Crossref
Carmelo Quarta, Kerstin Stemmer, Aaron Novikoff, Bin Yang, Felix Klingelhuber, Alex Harger, Mostafa Bakhti, Aimee Bastidas-Ponce, Eric Baugé, Jonathan E. Campbell, Megan Capozzi, Christoffer Clemmensen, Gustav Collden, Perla Cota, Jon Douros, Daniel J. Drucker, Barent DuBois, Annette Feuchtinger, Cristina Garcia-Caceres, Gerald Grandl, Nathalie Hennuyer, Stephan Herzig, Susanna M. Hofmann, Patrick J. Knerr, Konxhe Kulaj, Fanny Lalloyer, Heiko Lickert, Arek Liskiewicz, Daniela Liskiewicz, Gandhari Maity, Diego Perez-Tilve, Sneha Prakash, Miguel A. Sanchez-Garrido, Qian Zhang, Bart Staels, Natalie Krahmer, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan & Timo D. Müller. (2022) GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nature Metabolism 4:8, pages 1071-1083.
Crossref
Crossref
Louis DeRidder, Anjali Sharma, Kevin Liaw, Rishi Sharma, John John, Sujatha Kannan & Rangaramanujam M. Kannan. (2021) Dendrimer–tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis. Nanoscale 13:2, pages 939-952.
Crossref
Crossref
Catrin Sohrabi, Bunny Saberwal, Wei-Yao Lim, Dimitris Tousoulis, Syed Ahsan & Nikolaos Papageorgiou. (2020) Heart Failure in Diabetes Mellitus: An Updated Review. Current Pharmaceutical Design 26:46, pages 5933-5952.
Crossref
Crossref
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, Piyush Desai, Kamlesh Fatania, Satyanarayan Murthy, R. Balamurugan, Manish Agarwal, K. P. Singh, G. S. Kalra, Vipul Khandelwal, Ashish Singwala, Hemant Thacker, Rahul Tulle, Harish Rao, Mukund Kumbla, Parminder Singh, Ashok Khatri, Sumit Agrawal, R. N. Sarkar, Dinesh Agarwal, Girish Bhatia, R. P. Agarwal, Surender Kumar, P. R. Vamsi Krishna, Ajay Kumar Ajmani, Amit Asalkar, Indraneel Basu, Sudip Chatterjee, Vinod Kumar Pavithran, Rupam Das, Aniruddha Dharmadhikari, Vikram Vardhan, M. Madusudhan Babu, Nilanjan Sengupta, Srirang Abkari, R. Harikrishna, Rashmi Chovatia & Deven Parmar. (2020) Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). Cardiovascular Diabetology 19:1.
Crossref
Crossref
ZhengLong Liu, Jeffrey Ding, Timothy S. McMillen, Outi Villet, Rong Tian & Dan Shao. (2020) Enhancing fatty acid oxidation negatively regulates PPARs signaling in the heart. Journal of Molecular and Cellular Cardiology 146, pages 1-11.
Crossref
Crossref
Holli-Joi Sullivan, Xiaoyan Wang, Shaina Nogle, Siyan Liao & Chun Wu. (2020) To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. PPAR Research 2020, pages 1-24.
Crossref
Crossref
Charikleia Kalliora & Konstantinos Drosatos. (2020) The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation. Journal of Cardiovascular Pharmacology 76:5, pages 514-526.
Crossref
Crossref
Stefanie Wittrisch, Nora Klöting, Karin Mörl, Rima Chakaroun, Matthias Blüher & Annette G. Beck-Sickinger. (2020) NPY1R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression. Molecular Metabolism 31, pages 163-180.
Crossref
Crossref
Dustin K. Bauknight, Victoria Osinski, Siva Sai Krishna Dasa, Anh T. Nguyen, Melissa A. Marshall, Julia Hartman, Matthew Harms, Gavin O’Mahony, Jeremie Boucher, Alexander L. Klibanov, Coleen A. McNamara & Kimberly A. Kelly. (2019) Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects. PLOS ONE 14:11, pages e0224917.
Crossref
Crossref
Cheng, Tan, Low, Marvalim, Lee & Tan. (2019) Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. International Journal of Molecular Sciences 20:20, pages 5055.
Crossref
Crossref
Charikleia Kalliora, Ioannis D. Kyriazis, Shin-ichi Oka, Melissa J. Lieu, Yujia Yue, Estela Area-Gomez, Christine J. Pol, Ying Tian, Wataru Mizushima, Adave Chin, Diego Scerbo, P. Christian Schulze, Mete Civelek, Junichi Sadoshima, Muniswamy Madesh, Ira J. Goldberg & Konstantinos Drosatos. (2019) Dual PPARα/γ activation inhibitsSIRT1-PGC1α axis and causes cardiac dysfunction. JCI Insight 4:17.
Crossref
Crossref
Mohammad Alsalem, Mansour Haddad, Sara A. Aldossary, Heba Kalbouneh, Belal Azab, Aala Dweik, Amer Imraish & Khalid El-Salem. (2019)
Effects of Dual Peroxisome Proliferator-Activated Receptors
and
Activation in Two Rat Models of Neuropathic Pain
. PPAR Research 2019, pages 1-9.
Crossref
Crossref
Jing Li, Mei Luo, Minghua Hu, An-Yuan Guo, Xiangliang Yang, Qiong Zhang & Yanhong Zhu. (2018) Investigating the Molecular Mechanism of Aqueous Extract of Cyclocarya paliurus on Ameliorating Diabetes by Transcriptome Profiling. Frontiers in Pharmacology 9.
Crossref
Crossref
Sung Hee Choi, Sung Soo Chung & Kyong Soo Park. (2018) Re-highlighting the action of PPARγ in treating metabolic diseases. F1000Research 7, pages 1127.
Crossref
Crossref
Kristina Wallenius, Ann Kjellstedt, Pia Thalén, Lars Löfgren & Nicholas D. Oakes. (2013)
The PPAR
α
/
γ
Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization
In Vivo
in the Obese Zucker Rat
. PPAR Research 2013, pages 1-14.
Crossref
Crossref
Bengt Hamrén, K. Peter Öhman, Maria K. Svensson & Mats O. Karlsson. (2013) Pharmacokinetic‐Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology 52:9, pages 1317-1327.
Crossref
Crossref
Longxin Qiu, Hong Ye, Limei Chen, Yamin Hong, Fojin Zhong & Tingting Zhang. (2012) Red Clover Extract Ameliorates Dyslipidemia in Streptozotocin-induced Diabetic C57BL/6 Mice by Activating Hepatic PPARα. Phytotherapy Research 26:6, pages 860-864.
Crossref
Crossref
Kim Henriksen, Claus Christiansen & Morten Asser Karsdal. (2011) Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discovery Today 16:21-22, pages 967-975.
Crossref
Crossref
Adrian V. Hernandez, Ali Usmani, Anitha Rajamanickam & A. Moheet. (2011) Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus. American Journal Cardiovascular Drugs 11:2, pages 115-128.
Crossref
Crossref
Suzanne M. de la Monte, Maoyin Pang, Rajeev Chaudhry, Kevin Duan, Lisa Longato, Jade Carter, Jiyun Ouh & Jack R. Wands. (2011) Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatology Research 41:4, pages 386-398.
Crossref
Crossref
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, pages 117-152.
Crossref
Crossref
Monique Heald & Michael A. Cawthorne. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
35
51
.
Hyun Woo Jeong, Joo-Won Lee, Woo Sik Kim, Sung Sik Choe, Hyun Jung Shin, Gha Young Lee, Dongkyu Shin, Jun Hee Lee, Eun Bok Choi, Hyun Kyu Lee, Gyu Hwan Yon, Bongjun Cho, Hye Ryung Kim, Sung Hee Choi, Young Sun Chung, Seung Bum Park, Heekyoung Chung, Seonggu Ro & Jae Bum Kim. (2010)
A Nonthiazolidinedione Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist CG301360 Alleviates Insulin Resistance and Lipid Dysregulation in
db/db
Mice
. Molecular Pharmacology 78:5, pages 877-885.
Crossref
Crossref
Jakob Ribbing, Bengt Hamrén, Maria K. Svensson & Mats O. Karlsson. (2013) A Model for Glucose, Insulin, and Beta‐Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes. The Journal of Clinical Pharmacology 50:8, pages 861-872.
Crossref
Crossref
P Sanwald-Ducray, X Liogier D'ardhuy, C Jamois & L Banken. (2010) Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study. Clinical Pharmacology & Therapeutics 88:2, pages 197-203.
Crossref
Crossref
Hong Chen, Beatriz Dardik, Ling Qiu, Xianglin Ren, Shari L. Caplan, Bryan Burkey, Brian R. Boettcher & Jesper Gromada. (2010) Cevoglitazar, a Novel Peroxisome Proliferator-Activated Receptor-α/γ Dual Agonist, Potently Reduces Food Intake and Body Weight in Obese Mice and Cynomolgus Monkeys. Endocrinology 151:7, pages 3115-3124.
Crossref
Crossref
Michael J. Haas & Arshag D. Mooradian. (2010) Therapeutic Interventions to Enhance Apolipoprotein A-I-Mediated Cardioprotection. Drugs 70:7, pages 805-821.
Crossref
Crossref
Pradeep Natarajan, Kausik K. Ray & Christopher P. Cannon. (2010) High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology 55:13, pages 1283-1299.
Crossref
Crossref
Derek J Hausenloy & Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, pages 473-482.
Crossref
Crossref
S. Skalli, M. Baudrant & S. Halimi. (2009) Traitement du diab?te de type 2?: pourquoi les glitazars n?ont-ils pas ?t? introduits sur le march???. M?decine des Maladies M?taboliques 3:4, pages 406-411.
Crossref
Crossref
Uwe Grether, Agnes Bénardeau, Jörg Benz, Alfred Binggeli, Denise Blum, Hans Hilpert, Bernd Kuhn, Hans Peter Märki, Markus Meyer, Peter Mohr, Kurt Püntener, Susanne Raab, Armin Ruf & Daniel Schlatter. (2009) Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists. ChemMedChem 4:6, pages 951-956.
Crossref
Crossref
Agnes Bénardeau, Jörg Benz, Alfred Binggeli, Denise Blum, Markus Boehringer, Uwe Grether, Hans Hilpert, Bernd Kuhn, Hans Peter Märki, Markus Meyer, Kurt Püntener, Susanne Raab, Armin Ruf, Daniel Schlatter & Peter Mohr. (2009) Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorganic & Medicinal Chemistry Letters 19:9, pages 2468-2473.
Crossref
Crossref
JWA Van Der Hoorn, JW Jukema, LM Havekes, E Lundholm, G Camejo, PCN Rensen & HMG Princen. (2009) The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. British Journal of Pharmacology 156:7, pages 1067-1075.
Crossref
Crossref
Karin AM Jandeleit-Dahm, Anna Calkin, Chris Tikellis & Merlin Thomas. (2009) Direct antiatherosclerotic effects of PPAR agonists. Current Opinion in Lipidology 20:1, pages 24-29.
Crossref
Crossref
R.C.L. Page. 2009.
689
702
.
B Hamrén, E Björk, M Sunzel & MO Karlsson. (2008) Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment. Clinical Pharmacology & Therapeutics 84:2, pages 228-235.
Crossref
Crossref
E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini & N. Marchionni. (2008) Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 0:0, pages 080526191604039-???.
Crossref
Crossref
Herbert Schuster, Björn Fagerberg, Siôn Edwards, Tamas Halmos, Jerzy Lopatynski, Steen Stender, Grethe Stoa Birketvedt, Serena Tonstad, Ingrid Gause-Nilsson, Sigrún Halldórsdóttir & K. Peter Öhman. (2008) Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 197:1, pages 355-362.
Crossref
Crossref
Anna C. Calkin & Merlin C. Thomas. (2008) PPAR Agonists and Cardiovascular Disease in Diabetes. PPAR Research 2008, pages 1-12.
Crossref
Crossref
Barbara Caleen Hansen. 2008. The Metabolic Syndrome. The Metabolic Syndrome
373
386
.
Shi-Ying Ding, Xenia T. Tigno, Gheorghe T. Braileanu, Katsuhiko Ito & Barbara C. Hansen. (2007) A novel peroxisome proliferator–activated receptor α/γ dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56:10, pages 1334-1339.
Crossref
Crossref
Robert E RatnerShamik ParikhConrad Tou. (2016) Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diabetes and Vascular Disease Research 4:3, pages 214-221.
Crossref
Crossref
Burkhard GökeIngrid Gause-NilssonAnders Persson. (2016) The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diabetes and Vascular Disease Research 4:3, pages 204-213.
Crossref
Crossref
John PH WildingIngrid Gause-NilssonAnders Persson. (2016) Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diabetes and Vascular Disease Research 4:3, pages 194-203.
Crossref
Crossref
Harold BaysJennifer McElhattanBrian S Bryzinski. (2016) A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 4:3, pages 181-193.
Crossref
Crossref
Bjorn FagerbergHerbert SchusterGrethe Støa BirketvedtSerena TonstadKarl Peter ÖhmanIngrid Gause-Nilsson. (2016) Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARα/γ agonist, tesaglitazar. Diabetes and Vascular Disease Research 4:3, pages 174-180.
Crossref
Crossref
Serena Tonstad, Kjetil Retterstøl, Leiv Ose, K. Peter Öhman, Magnus B. Lindberg & Maria Svensson. (2007) The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Metabolism 56:9, pages 1285-1292.
Crossref
Crossref
Heike Hellmold, Hui Zhang, Ulf Andersson, Bo Blomgren, Tom Holland, Anna-Lena Berg, Marie Elebring, Niclas Sjögren, Krister Bamberg, Björn Dahl, Rolf Westerberg, Birgitta Dillner, Jonathan Tugwood, Jonathan Tugwood, Ruth Roberts, Erik Lundholm, German Camejo, Inger Skånberg & John Evans. (2007) Tesaglitazar, a PPARα/γ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats. Toxicological Sciences 98:1, pages 63-74.
Crossref
Crossref
Feng Chang, Linda A Jaber, Helen D Berlie & Mary Beth O'Connell. (2007) Evolution of Peroxisome Proliferator-Activated Receptor Agonists. Annals of Pharmacotherapy 41:6, pages 973-983.
Crossref
Crossref
Young-Ran KangChoong-Hwan KwakJin-Yong Hwang. (2007) Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-α Agonist for Treating Cardiovascular Disease. Korean Circulation Journal 37:12, pages 599.
Crossref
Crossref